TheraCellix™️ has successfully met the requirements assessed during an audit conducted by Indonesia’s Ministry of Health (Kementerian Kesehatan Republik Indonesia / Kemenkes) on 13 August 2026, in connection with its application for Risk-Based Business Licensing (Perizinan Berusaha Berbasis Risiko) for Health Support Services Activities (Aktivitas Pelayanan Penunjang Kesehatan).
Following the assessment, the corresponding certificate was issued on 9 September 2026, marking an important milestone in TheraCellix™️’s regulatory compliance journey and the development of its operations in the stem cell manufacturing sector. [View the certificate].
The assessment underscores the importance of meeting applicable regulatory requirements and establishing appropriate operational and quality management systems for healthcare support services activities.
TheraCellix™️ remains committed to strengthening its systems and maintaining applicable standards to support safe, reliable, and responsible operations.
This milestone represents a meaningful step forward for TheraCellix™️ as it continues to advance its operational readiness and commitment to quality within Indonesia’s biotechnology and healthcare landscape.
